HETA for Clinical

HETA

Measures the quality of a scanned H&E slide before analysis, so the lab can decide whether to proceed, rescan or recut.

Quality failures caught at scanning

Quality failures surface before review or analysis begins.

Consistent acceptance criteria

One measured standard across operators, sites and shifts.

HETA

Identifies and annotates tumor across the whole slide, so malignant cases are flagged at scanning.

Urgent cases read first

Malignant cases move ahead of the arrival-order worklist.

Ready for review

Tumor is pre-marked, so pathologists can confirm and order stains in one pass.

HETA

Counts mitoses across the whole tumor area and reports both index and count, so grading doesn’t hinge on which fields were picked.

Pathologist time

Removes slow manual counting in grading-intensive cancers.

Reproducible grading

The same count every time, reducing interobserver variability.

HETA

Measures tumor cell content and proposes which region to analyze, so labs know a sample is sufficient before molecular testing.

Fewer failed tests and repeats

An estimated 10–20% of molecular tests fail on insufficient tumor content.

Conserve tissue

Fewer repeat biopsies or excisions.

HETA Clinical: faster triage, fewer failed tests